Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

View:
Post by brad129 on Aug 08, 2022 11:20am

Share price

If they had $600k end of last quarter and have 4-600k end of this quarter, where would the stock head, up or down? Hahaha
Comment by LithLover on Aug 08, 2022 11:44am
Operating costs last quarter were $2.6 million. Total operating costs of $9.2 million for full 2021. If they were able to cut costs and/or bring in enough revenues to stay neutral.  Say $2-2.2 million in revenues and cutting costs or $3 million in revenues with existing costs, either way that would be a very big step.  With annual revenues at $10-12 million while remaining cash flow ...more  
Comment by 4real4ever on Aug 08, 2022 2:35pm
That means you think the share price can't be higher than $0,60 and $0,80 LithLover (824) User Actions   August 15, 2016 - 04:45 PM 89 Reads Post# 25143634 Thanks. Love the low float. This could pop to $1 in no time flat. Many years before the 8:1 consolidation Where's your $8 six years later
Comment by Mykndrsn on Aug 10, 2022 10:53am
Important to remember due to segment acconting rules accounts receivable aren't included in revenue. Everything is delayed until the bill is paid. Creates an obvious lag in reporting sales. 
Comment by brad129 on Aug 10, 2022 11:04am
Everything I've read is you have to pay up front to receive the tests, you have done the test, did they bill you or did you have to pay up front?  we haven't seen any Hospital deals where terms could be part of the equation.  
Comment by frewil11 on Aug 10, 2022 12:21pm
It is starting to look like even through the financials we will still have no idea of how how many Aristotle tests were paid for and if the numbers are on a upward trend , after nearly a year and a half after launch and we still have no idea is pretty frustrating , no wonder there is zero interest here. JMHO.
Comment by Mykndrsn on Aug 10, 2022 12:38pm
I think it's safe to say to many sales involve terms. Ichor, large employers etc. Individuals not so much. 
Comment by Liked2Think on Aug 08, 2022 12:16pm
your grasping at straws just like what has been done with this company since day one. Stagezero management does not deserve investors that hope as much as you and others and I used to.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities